Cannabidiol in Anxiety and Sleep: A Large Case Series [S. Shannon, MD, N. Lewis, ND; H. Lee, PA-C; and S. Hughes, PhD]
“A large retrospective case series at a psychiatric clinic involving clinical application of CBD for anxiety and sleep complaints as an adjunct to usual treatment. The retrospective chart review included monthly documentation of anxiety and sleep quality in 103 adult patients. The final sample consisted of 72 adults presenting with primary concerns of anxiety or poor sleep. Anxiety scores decreased within the first month in 57 patients (79.2%) and remained decreased during the study duration.” Additionally, the sleep scores demonstrated mild improvement.
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis [P.F. Whiting; R.F. Wolff; S. Deshpande; M. Di Nisio; et al]
Whiting and his team performed a systematic review of the benefits of cannabinoids, sourcing material from 28 well-respected databases, and focusing on randomized clinical trials of cannabinoids for the multiple indications, including chronic pain, and spasticity due to multiple sclerosis or paraplegia. A total of 79 trials (6462 participants) were included.
Conclusion: Overall, there was definite evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity.
The Endocannabinoid System, Cannabinoids, and Pain [P.g.Fine, MD; and M.J. Rosenfeld, MS, PhD]
This study concluded that, “The phytocannabinoids have efficacy in the treatment of various chronic pain conditions with greatest promise as a therapeutic adjunct in treating peripheral and central neuropathic pain and inflammation-mediated chronic pain … The direction for the future resides in the development of orally administered, highly bioavailable, non-psychoactive phytocannabinoid products that also take advantage of the entourage effect, to provide the millions of people living with debilitating pain a comparatively safe and effective form of relief.”
CBD and your Pets
Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy Stephanie McGrath DVM, MS; Lisa R. Bartner DVM, MS; Sangeeta Rao BVSc, PhD; et al. which noted “a significant reduction in seizure frequency was achieved for dogs in the CBD group” versus dogs given a placebo.
Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs. Gamble LJ; Boesch JM; Frye CW; et al. for which the conclusion ws “canine brief pain inventory and Hudson activity scores showed a significant decrease in pain and increase in activity (p < 0.01) with CBD oil. Veterinary assessment showed decreased pain during CBD treatment.”